FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, namely to methods for the treatment of an inflammatory disease or condition and reduction or inhibition of an immune response that include the injection of therapeutically effective amount of CD32B x CD79B-binding molecule that is capable of immune-specifically binding CD32B epitope and CD79B epitope and includes: (A) VLCD32B domain that contains an amino acid sequence SEQ ID NO: 30; (B) VHCD32B domain that contains an amino acid sequence SEQ ID NO: 31; (C) VLCD79B domain that contains an amino acid sequence SEQ ID NO: 32; (D) VHCD79B domain that contains an amino acid sequence SEQ ID NO: 33. The specified CD32B x CD79B-binding molecule is injected in a dose from about 3 to about 10 mg/kg and in a dosing mode of one dose every 3 weeks (Q3W). The group of inventions also relates to the use of the specified CD32B x CD79B-binding molecule for the treatment of an inflammatory disease or condition and for the reduction or inhibition of an immune response.
EFFECT: group of inventions provides for linear pharmacokinetics of a drug that demonstrates more than 50% binding of B-cells for a long time.
14 cl, 47 dwg, 13 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY USING NON-DEPLETION B-CELL INHIBITORS | 2020 |
|
RU2821892C2 |
VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
MOLECULES WITH CD45 AND CD79 SPECIFICITY | 2015 |
|
RU2747980C2 |
COVALENT DIABODIES AND USE THEREOF | 2009 |
|
RU2744176C2 |
BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
MOLECULES WITH SPECIFICITY WITH RESPECT TO CD79 AND CD22 | 2015 |
|
RU2743590C2 |
COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
Authors
Dates
2022-05-19—Published
2017-06-06—Filed